Add like
Add dislike
Add to saved papers

miR-133a functions as a tumor suppressor and directly targets FSCN1 in pancreatic cancer.

MicroRNA-133a has been proven downregulated in many human malignancies and correlated with tumor progression. However, the roles of miR-133a and its related molecular mechanisms in pancreatic cancer are still not clear. Here we found that miR-133a expression was significantly downregulated in pancreatic cancer tissue samples and cell lines by using quantitative real-time RT-PCR. Decreased miR-133a expression was significantly correlated with aggressive clinicopathological features and poor survival. In addition, miR-133a was identified to be a tumor suppressor, as transfection of miR-133a mimics in PANC-1 cells was able to reduce cell proliferation, invasion, and migration and promote cell apoptosis in vitro and suppress tumorigenicity in vivo. Further, we observed an obvious inverse correlation between FSCN1 and miR-133a levels in tumor samples, and FSCN1 was confirmed as a direct target of miR-133a by using Luciferase Reporter Assay. These findings suggest an important role of miR-133a in the molecular etiology of cancer and implicate its potential application in gene therapy of pancreatic cancer.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app